

ESPS Peer-review Report

Name of Journal: World Journal of Experimental Medicine

ESPS Manuscript NO: 3825

Title: Obesity, insulin resistance, adipocytokines and breast cancer: new biomarkers and attractive therapeutic targets

Reviewer code: 00081174

Science editor: Wen, Ling-Ling

Date sent for review: 2013-05-26 19:09

Date reviewed: 2013-06-12 19:52

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

Comments to Author:

First of all I would like to thank you for such a comprehensive review on the exciting topic of obesity, insulin resistance in relation to breast cancer.

The following additions can be done in this article before publication:

1. Please define the clinical definition of metabolic syndrome in the introduction.
2. Role of Oxidative stress can be done separately.
3. Need to describe role of Sirtunins.
4. Please describe the basic cutoff values for adiponectin levels.

Serum adiponectin levels are generally measured in the range of 2 to 20 g/mL. Median levels of adiponectin in healthy individuals with a BMI between 20 and 25 kg/m² are reported as 8 g/mL for men and approximately 12.5 g/mL for women, although values vary by race and assay methodology. Chelbowki et al JCO 2011...

5. Atleast describe one clinical study with each biomarker in detail, so the article can be of interest for clinicians.

For example: [Clin Biochem.](#) 2013 May;46(7-8):584-90. doi: 10.1016/j.clinbiochem.2013.01.001. Epub 2013 Jan 13. This is your own publication.

Serum resistin: a biomarker of breast cancer in postmenopausal women? Association with clinicopathological characteristics, tumor markers, inflammatory and metabolic parameters.

[Dalamaga M](#), [Sotiropoulos G](#), [Karmaniolas K](#), [Pelekanos N](#), [Papadavid E](#), [Lekka A](#).